

Index to Volume Twenty

Index of Issues: January–February 1–60; March–April 61–120; May–June 121–180; July–August 181–242; September–October 243–300; November–December 301–360.

INDEX OF AUTHORS

A
Abdullah AN, 344
Addiss DG, 28
Agacidan A, 236
Alain Brueat Physician Group,
 51
Albrecht KD, 140
Almaraz A, 257
Anderson JE, 201
Anderson R, 168
Anderson RM, 181
Ashley RL, 239
Ayowa OB, 96

B
Baddour LM, 238
Badur S, 236
Baker C, 198
Baker SA, 352
Baker SL, 45
Ballard RC, 5
Bansal J, 220
Barditch P, 346
Barnes W, 279
Bassa AGH, 164
Bauer HM, 274
Becker TM, 286
Beebe JL, 140
Benes S, 227
Bergeron MG, 314
Black JR, 262
Bolan G, 14
Botcherby M, 21
Bottles K, 121
Boyer R, 100
Bradet R, 100
Bramdev A, 164
Bratos MA, 257
Brinton LA, 279
Brock S, 36
Brown JE, 96
Brown RC, 96
Brunham RC, 168
Bucquet D, 51
Budd J, 89

C
Cadell DM, 274
Callahan JD, 220
Castriciano S, 301
Castro I, 314
Cates W Jr, 174

D
Dahlöf LG, 10
Dalessio J, 230
Dangor Y, 5
Daniell FD, 294
Danielsson D, 143
Dan M, 158
Darougar S, 61
Davis CH, 248
Davis JP, 28
Debby A, 158
de la Maza LM, 352
DiGiorgio-Haag L, 307
Dines RJ, 61
Douglas JM Jr, 290
Dowda H, 334
Draft K, 227
Dragavon J, 230
Duval B, 100

E
Eiros JM, 257
Ekstrand M, 307
Epp J, 279
Ernst AA, 66

F
Finelli L, 89
Forslin L, 143
Fortin C, 100

G
Gamble WB Jr, 334
Garnett G, 168

H
Handsfield HH, 237, 269, 290
Hanna N, 21
Hart G, 126
Hawkins RE, 294
Hayes C, 36
Hay PE, 1
Heaton CG, 70
Hearst N, 14
Hildesheim A, 274, 279
Hildesheim A, 286
Hillman RJ, 21
Hilton JF, 307
Hippeläinen M, 321
Holmes KK, 41, 214, 230
Hook EW III, 269
Hoosen AA, 164, 265
Hörting-Müller I, 243
Hounsa A, 100
Hunt WC, 286
Hyams KC, 36, 294

I
Ison C, 105
Ison CA, 329

J

K
Jang D, 152, 301
Johansson E, 143
Jones JL, 334
Jones RB, 269
Jones S, 279
Joyce CF, 105
Jutto P, 334

L
Lampe M, 214
Landers DV, 121
Larroque B, 51
Lee FK, 230
Legault J, 198
Lindan C, 14
Lind I, 338
Ludka D, 28
Luger A, 110
Luinstra K, 301
Luinstra KE, 152

M
Mahnès G, 100
Mahoney MC, 209
Mahony J, 301
Mahony JB, 152
Malone JD, 294
Manos MM, 274, 279, 286
Marsiglia VC, 220
Martin DH, 66
Martín-Rodríguez JF, 257
McCormack WM, 227, 262, 269
McCusker J, 81
McKenzie P, 1
McLaughlin CC, 209
McMaster J, 168
Meheus A, 194
Mercer L, 137
Messeri P, 70
Messiah A, 51
Mettenal J-F, 51
Metzger BB, 209
Meyer P, 334
Michalek AM, 209
Mogabgab WJ, 269
Moi H, 143
Moodley J, 164
Morrison DM, 352

Index to Volume Twenty

Index of Issues: January–February 1–60; March–April 61–120; May–June 121–180; July–August 181–242; September–October 243–300; November–December 301–360.

INDEX OF AUTHORS

A
Abdullah AN, 344
Addiss DG, 28
Agacidan A, 236
Alain Brueat Physician Group,
 51
Albrecht KD, 140
Almaraz A, 257
Anderson JE, 201
Anderson R, 168
Anderson RM, 181
Ashley RL, 239
Ayowa OB, 96

B
Baddour LM, 238
Badur S, 236
Baker C, 198
Baker SA, 352
Baker SL, 45
Ballard RC, 5
Bansal J, 220
Barditch P, 346
Barnes W, 279
Bassa AGH, 164
Bauer HM, 274
Becker TM, 286
Beebe JL, 140
Benes S, 227
Bergeron MG, 314
Black JR, 262
Bolan G, 14
Botcherby M, 21
Bottles K, 121
Boyer R, 100
Bradet R, 100
Bramdev A, 164
Bratos MA, 257
Brinton LA, 279
Brock S, 36
Brown JE, 96
Brown RC, 96
Brunham RC, 168
Bucquet D, 51
Budd J, 89

C
Cadell DM, 274
Callahan JD, 220
Castriciano S, 301
Castro I, 314
Cates W Jr, 174

D
Dahlöf LG, 10
Dalessio J, 230
Dangor Y, 5
Daniell FD, 294
Danielsson D, 143
Dan M, 158
Darougar S, 61
Davis CH, 248
Davis JP, 28
Debby A, 158
de la Maza LM, 352
DiGiorgio-Haag L, 307
Dines RJ, 61
Douglas JM Jr, 290
Dowda H, 334
Draft K, 227
Dragavon J, 230
Duval B, 100

E
Eiros JM, 257
Ekstrand M, 307
Epp J, 279
Ernst AA, 66

F
Finelli L, 89
Forslin L, 143
Fortin C, 100

G
Gamble WB Jr, 334
Garnett G, 168

H
Handsfield HH, 237, 269, 290
Hanna N, 21
Hart G, 126
Hawkins RE, 294
Hayes C, 36
Hay PE, 1
Heaton CG, 70
Hearst N, 14
Hildesheim A, 274, 279
Hildesheim A, 286
Hillman RJ, 21
Hilton JF, 307
Hippeläinen M, 321
Holmes KK, 41, 214, 230
Hook EW III, 269
Hoosen AA, 164, 265
Hörting-Müller I, 243
Hounsa A, 100
Hunt WC, 286
Hyams KC, 36, 294

I
Ison C, 105
Ison CA, 329

J

K
Jang D, 152, 301
Johansson E, 143
Jones JL, 334
Jones RB, 269
Jones S, 279
Joyce CF, 105
Jutto P, 334

L
Lampe M, 214
Landers DV, 121
Larroque B, 51
Lee FK, 230
Legault J, 198
Lindan C, 14
Lind I, 338
Ludka D, 28
Luger A, 110
Luinstra K, 301
Luinstra KE, 152

M
Mahnès G, 100
Mahoney MC, 209
Mahony J, 301
Mahony JB, 152
Malone JD, 294
Manos MM, 274, 279, 286
Marsiglia VC, 220
Martin DH, 66
Martín-Rodríguez JF, 257
McCormack WM, 227, 262, 269
McCusker J, 81
McKenzie P, 1
McLaughlin CC, 209
McMaster J, 168
Meheus A, 194
Mercer L, 137
Messeri P, 70
Messiah A, 51
Mettenal J-F, 51
Metzger BB, 209
Meyer P, 334
Michalek AM, 209
Mogabgab WJ, 269
Moi H, 143
Moodley J, 164
Morrison DM, 352

INDEX OF AUTHORS

Morris RE, 198
 Morse S, 353
 Mosquera C, 147
 Moss TR, 61
 Mulchahey K, 45
 Murphy DP, 209

N

Nadeau D, 100
 Nahmias AJ, 230
 Nathan M, 61
 Ndoye I, 194
 Nerad S, 243
 Newhall J, 353
 Noegel R, 118
 Nutter C, 353

O

Oh MK, 45
 Omar MAK, 265
 Orduña A, 257
 Orduña Prieto E, 257
 Ortiz de Lejarazu R, 257

P

Palacio V, 147
 Parmenter CA, 286
 Pass MA, 45
 Pass RF, 45
 Patton DL, 214
 Peer AKC, 265

R

Radebe F, 5
 Rand S, 346
 Raulston JE, 248
 Rau MP, 140
 Reimann K, 338
 Renton A, 105
 Rodriguez-Torres A, 257
 Rompal AM, 346
 Rosenberg MJ, 41
 Rouzioux C, 51
 Rush BB, 274
 Ryait BK, 21

S

Saarikoski S, 321
 Sampedro A, 147
 Samra Z, 158
 Schachter J, 121, 239, 307
 Schiffman MH, 274, 279
 Schrader M, 118
 Schramm N, 248
 Scott DR, 274
 Seedat MA, 265
 Sellors J, 301

T

Taylor-Robinson D, 1, 21
 Tchabo J-G, 279
 Tekki N, 329
 Teodorowicz L, 243
 Thomas BJ, 1

V

van den Ende J, 265
 Van De Velde L, 194
 Van Dyck E, 194
 Vaughn ML, 28

W

Sellors JW, 152
 Serour F, 192
 Shafer M-A, 307
 Shalwitz J, 307
 Shangold GA, 137
 Shangold MM, 137
 Sharp TW, 294
 Shoupe D, 137
 Smith BL, 227
 Soper DE, 137
 Spitalny KC, 89
 Stamm WE, 214
 Starý A, 243
 Stevens CE, 230
 Stoddard AM, 81
 Sung ML, 121
 Syrjänen K, 321
 Syrjänen S, 321

Z

Zahel B, 243
 Zukut H, 158
 Zapka JG, 81
 Zeng W, 214
 Zenilman JM, 346
 Zhang X, 220
 Zorn M, 81
 Zwickl B, 262

INDEX OF SUBJECTS

A

Adolescents
 female
 isolated asymptomatic urethral *C. trachomatis* infection in, 198
 pregnant, *C. trachomatis* infection in, 45
 male, drug use and sexual behavior in, 307

Africa
 female granuloma inguinale in, 164
 intravaginal foreign substance use in, 96
 sub-Saharan, chlamydial infection in, 168

AIDS. *See under* Human immunodeficiency virus

American Social Health Association (ASHA)
 funding efforts of, 59, 240, 299
 status report of, 179, 240, 299

Amies' transport medium, for *H. ducreyi*, 5

Ampicillin/sulbactam, for syphilis, 237 (letter)

Anal human papillomavirus infection, cytologic diagnosis vs. DNA hybridization studies for, 147

Anal intercourse. *See* Sexual behavior, high-risk

Anogenital warts. *See* Condylomata acuminata

Antibiotic resistance, of *Neisseria gonorrhoeae* in Nicaragua, 314

tetM determinant detection for, 329

Antibiotics. *See also* specific agents
 anti-inflammatory drugs with, for chlamydial salpingitis, 121

Antibodies, to nongenital chlamydia, impact of on *C. trachomatis* serology tests, 61

Antifungal therapy, empiric, for vaginal infections in diabetics, 265

Anti-inflammatory drugs, for chlamydial salpingitis, infertility and, 121

ASHA. *See* American Social Health Association (ASHA)

B

Bacterial vaginosis, ofloxacin and metronidazole for, 262

C

Cefixime, low-dose, for gonorrhea, 290

Cefotaxime, for gonorrhea, 269

Ceftriaxone, for gonorrhea, 227, 269

Chlamydia spp., nongenital, antibodies to, impact of on *C. trachomatis* serology tests, 61

Chlamydia trachomatis
 Chlamydiazyme test for, false-positive results of, gender and genital specimen type and, 301
 detection of, in males, 1
 as main cause of pelvic inflammatory disease, 158
 serology tests for, impact of *C. pneumoniae* and *C. psittaci* on, 61
 Syva enzyme immunoassay grey zone specimens of, confirmatory testing of, 140

Chlamydia trachomatis infection

decreased prevalence of, 28
 isolated urethral asymptomatic, in adolescent girls, 198
 in male partners of women with acute pelvic inflammatory disease, 143

pathogenesis of, in vitro human epithelial cell culture for, 249
 in sub-Saharan Africa, 164

in young pregnant teenagers, 45

Chlamydia trachomatis salpingitis

addition of anti-inflammatory drugs to antimicrobial therapy for, infertility and, 121
 pathogenesis of, spermatozoa and, 214

Chlamydiazyme test, false-positive results of, gender and genital specimen type and, 301

Cocaine abuse. *See also* Drug abuse

condom use in, effect of AIDS education on, 81
 high-risk sexual activity in. *See* Sexual behavior, high-risk
 syphilis incidence and, 66, 89

Columbian theory, of origin of syphilis, 110

Condom, female, in vaginal trichomoniasis prevention, 137

Condom use

before and after AIDS education, in drug abusers, 81
 in high-risk heterosexual population, 14
 sexual behavior and, in never-married women, 201

Condylomata acuminata

cryotherapy vs. trichloroacetic acid for, 344
 cytologic diagnosis vs. DNA hybridization studies for, 147
 human papillomavirus DNA in, in males, 21
 physical and psychological effects of, in females, 5

Contact tracing, for gonococcal infections, 181

Contraception

sexually transmitted diseases and, 174

Crack cocaine. *See* Cocaine; Drug abuseCryotherapy, for condylomata acuminata, vs. trichloroacetic acid, 344
 Cytomegalovirus infection, heterosexual transmission of, 36

D

Diabetes mellitus, vaginal infections in, empiric antifungal therapy for, 265

DNA, human papillomavirus, in urogenital tract of men with anogenital warts, 21

DNA hybridization studies, vs. cytologic diagnosis, for anal human papillomavirus infection, 147

DNA probe assay, vs. culture, for *N. gonorrhoeae* detection, 243

Doxycycline, for early latent syphilis, asymptomatic neurosyphilis after, 346

Drug abuse

condom use in, effect of AIDS education on, 81
 high-risk sexual behavior and. *See also* Sexual behavior, high-risk
 in male adolescents, 307
 syphilis incidence and, 66, 89

Drug resistance, of *Neisseria gonorrhoeae* in Nicaragua, 314

tetM determinant detection for, 329

Drug therapy. *See* Antibiotics; Antifungal therapy; Anti-inflammatory drugs

Dry sex, intravaginal substances for, in Zaire, 96

E

Education

for condom use, in drug abusers, 70, 81

for safe sex practices

effectiveness of, 51

video instruction for, 70

Emotional aspects

of anogenital warts, in females, 5
 of herpes simplex virus infection, 77

Enoxacin, for gonorrhea, 227

F

Family planning

sexually transmitted diseases and, 174

Female condom, in vaginal trichomoniasis prevention, 137

Finland, human papillomavirus infection in, prevalence of and risk factors for, in healthy males, 321

Fluorescent antibody test, for *C. trachomatis* Syva enzyme immunoassay grey zone specimens, 140

Foreign substances, intravaginal, in Zairian women, 96

G

Genital herpes, psychosocial aspects of, 77

Genital warts. *See* Condylomata acuminata

Gonococcal infections, epidemiology of, contact tracing and, 181

Gonorrhea. *See also* *Neisseria gonorrhoeae*

ampicillin/sulbactam for, 237 (letter)

cefotaxime and ceftriaxone for, 269

enoxacin and ceftriaxone for, 227

low-dose cefixime for, 290

in male partners of women with acute pelvic inflammatory disease, 143

Granuloma inguinale, in women, 164

Greenland, epidemiology of non-penicillinase-producing *N. gonorrhoeae* isolates in, 338

H

Haemophilus ducreyi, transport media for, 5

Health teaching

for condom use, for drug abusers, 70, 81

for safe sex practices

effectiveness of, 51

video instruction for, 70

Hepatitis B and C

heterosexual transmission of, 36

with sexually transmitted diseases, in clinic and emergency room populations, 220

Hepatitis B transmission, syphilis and, in female prostitutes, 257

Herpes simplex virus infection, psychosocial aspects of, 77

Herpes simplex virus type 2, seroprevalence of, underestimation of by microneutralization assay, 230

High-risk behavior. *See* Drug abuse; Sexual behavior, high-risk

Homosexuals, HIV infection in, risk factors for in "safer sex" era, 51

Human immunodeficiency virus antibody, in clinic patients refusing and accepting testing, 334

Human immunodeficiency virus infection

antecedent hepatitis B or C and, 220

homosexually acquired, risk factors for in "safer sex" era, 51

virucides in prevention of, 41

Human papillomavirus DNA, in urogenital tract of men with anogenital warts, 21

Human papillomavirus infection

anal, cytologic diagnosis vs. DNA hybridization studies for, 147

anogenital warts in. *See* Condylomata acuminata

prevalence and risk factors for, in healthy Finnish males, 321

risk factors for

in cytologically normal population, 286

in high-risk population, 279
 in low-risk population, 274
Human T-cell lymphotropic virus infection, antecedent hepatitis B or C and, 220

I

Infertility, chlamydial salpingitis and, 121
 in sub-Saharan Africa, 168
Intercourse. See Sexual behavior

L

Leukocyte esterase urine strip, in *C. trachomatis* screening, in asymptomatic males, 152

M

Media, transport, for *H. ducreyi*, 5
Metronidazole, for bacterial vaginosis, 262
Microneutralization assay, underestimation of HSV-2 seroprevalence by, 230
Military personnel
 heterosexual transmission of viral hepatitis and cytomegalovirus infection in, 36
 risk factors for sexually transmitted diseases in, 294

N

Neisseria gonorrhoeae
 DNA probe test vs. culture for, 243
 infection with. *See Gonorrhea*
 multiresistant strains of, in Nicaragua, 314
 non-penicillinase-producing, epidemiology of in Greenland, 338
 persistence of multiple serovars of, 105
tetM determinant in, detection of, 329
Neurosyphilis, asymptomatic, after doxycycline for early latent syphilis, 346

O

Ofloxacin, for bacterial vaginosis, 262

P

Papular pearly penile pearls, 192
Patient education
 condom use and, in drug abusers, 70, 81
 for safe sex practices
 effectiveness of, 51
 video instruction for, 70
Pelvic inflammatory disease
 etiology of, 158
 gonorrhea, genital chlamydial infection, and nonspecific urethritis in male partners and, 143
Penis, artificial nodules in, 192

Pregnancy
 adolescent, *C. trachomatis* infection and, 45

Prostitutes
 hepatitis B transmission in, syphilis and, 257
 Turkish, syphilis in, 236 (letter)

Psychosocial aspects
 of anogenital warts, in females, 5
 of herpes simplex virus infection, 77

S

Safe sex education
 condom use and, in drug abusers, 70, 81
 effectiveness of, 51
 video instruction in, 70

Salpingitis, chlamydial. See also *Chlamydia trachomatis* infection
 addition of anti-inflammatory drugs to antimicrobial therapy for, infertility and, 121

spermatozoa in pathogenesis of, 214
 in sub-Saharan Africa, 168

Screening. See also specific tests
 for *C. trachomatis*

in asymptomatic males, leukocyte esterase urine strip for, 152
Chlamydiazyme test for, false-positive results in, 301
 impact of *C. pneumoniae* and *C. psittaci* on, 61
 in males, 1
 Syva enzyme immunoassay grey zone specimens in, confirmatory testing of, 140
 microneutralization assay for, underestimation of HSV-2 prevalence by, 230
 for syphilis, rapid plasma reagent teardrop card test for, 194

Sexual behavior
 condom use and, in never-married women, 201
 high-risk
 chlamydial infection and, in pregnant adolescents, 45
 condom use and, 14
 drug use and, in high-risk male adolescents, 307
 educational interventions for, 51, 70, 81
 HIV infection and, safe sex education and, 51
 syphilis and, 66, 89
 intravaginal substance use and, in Zaire, 96

Sexually transmitted diseases
 accelerated prevention campaign for, 118
 with blood-borne infections, in clinic and emergency room populations, 221
 family planning and, 174

intention to seek prompt care for, in college students, 100
 prevention of, education for, 51, 70, 81
 risk profiles and epidemiologic interrelationships of, 126

South Africa, female granuloma inguinale in, 164
Spermatozoa, in *C. trachomatis* infection pathogenesis, 214

Spermicides, in HIV infection prevention, 41

Sulbactam. See Ampicillin/sulbactam

Syphilis
 antecedent, mortality patterns and, 209
 in cocaine abusers, 66, 89
 early
 latent, doxycycline for, asymptomatic neurosyphilis after, 346
 risk factors for, 89
 hepatitis B transmission and, in female prostitutes, 257
 origins of, Columbian theory of, 110
 rapid plasma reagent teardrop card test for, for field screening, 194
 in Turkish prostitutes, 236 (letter)
 Syva direct fluorescent antibody test, for *C. trachomatis* grey zone specimens, 140

T

Teenagers. *See Adolescents*
tetM determinant, in *N. gonorrhoeae*, detection of, 329
Tetracycline-resistant *Neisseria gonorrhoeae*, *tetM* determinant in, detection of, 329
Transport media, for *H. ducreyi*, 5
Trichloracetic acid, for condylomata acuminata, vs. cryotherapy, 344
Trichomoniasis, prevention of, by female condom, 137
Turkish prostitutes, syphilis in, 236 (letter)

U

Urethritis
chlamydial. *See also Chlamydia trachomatis* infection
asymptomatic, in adolescent girls, 198
leukocyte esterase urine strip screening for, 152
nonspecific, in male partners of women with acute pelvic inflammatory disease, 143
Urine specimen, for *C. trachomatis* detection, in males, 1
Urine strip, leukocyte esterase, in *C. trachomatis* screening, in asymptomatic males, 152

V

Vagina, foreign substance insertion in, in Zaire, 96
Vaginal infections
in diabetics, empiric antifungal therapy for, 265
ofloxacin and metronidazole for, 262
Vaginal spermicides, in HIV infection prevention, 41
Vaginal trichomoniasis, prevention of, by female condom, 137
Video instruction, for safe sex practices, 70
Viral hepatitis
heterosexual transmission of, 36
with sexually transmitted diseases, in clinic and emergency room populations, 220
syphilis and, in female prostitutes, 257
Virucides, in HIV infection prevention, 41

W

Warts, anogenital. *See Condylomata acuminata*

Z

Zaire, intravaginal substance use in, 96

